Infectious disease
SARS was called the first pandemic of the 21st century. It would not be the last. Nor would it be the most deadly.
When tested in mice, the vaccine, which is delivered through a fingertip-sized patch, produced the antibodies specific to the novel coronavirus that causes COVID-19.
Novartis announced that, with Incyte, it is launching a Phase III clinical trial to determine if their cancer drug Jakavi (ruxolitinib) can be used to treat COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
The U.S. Food and Drug Administration approved the first blood test that looks for the antibodies against the novel coronavirus that causes COVID-19.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
A late-stage lung cancer drug under development by OSE Immunotherapeutics met its 12-month primary endpoint for survival rates following a Step-1 analysis.
Pinpoint Therapeutics believes that its approach to treat therapy-resistant cancers also may be effective against COVID-19.
With all the similarities, it should be emphasized that there are several significant differences between the two pandemics.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
PRESS RELEASES